Press Release
Category Added in a WPeMatico Campaign
-
FIRST FINANCIAL BANKSHARES NAMED THE #5 TOP-PERFORMING PUBLIC BANK IN THE NATION BY S&P GLOBAL MARKET INTELLIGENCE
ABILENE, Texas, April 21, 2026 /PRNewswire/ — First Financial Bankshares, Inc. (NASDAQ: FFIN) the parent company of First Financial Bank,…
Read More » -
800 Pound Gorilla Launches Gorilla Comedy+ Streaming Service with Cineverse
Launching May 5, Gorilla Comedy+ Will Feature New Stand-Up Specials From Patton Oswalt, Pete Holmes, Jourdain Fisher, Emmy Blotnick, Nish…
Read More » -
SWEP Expands Heat Transfer Offering Through New Strategic Partnership
DOWNERS GROVE, Ill., April 21, 2026 /PRNewswire/ — SWEP, part of Dover (NYSE: DOV) and a world-leading supplier of brazed…
Read More » -
Johnson Controls Announces Second Quarter 2026 Earnings Conference Call Webcast and “Going to Gemba Day” for Investors and Sell-Side Analysts
CORK, Ireland, April 21, 2026 /PRNewswire/ — Johnson Controls International plc (NYSE: JCI), a global technology leader in energy efficiency,…
Read More » -
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ — BioLife Solutions,…
Read More » -
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
DUBLIN, April 21, 2026 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter…
Read More » -
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and…
Read More » -
Resideo To Release First Quarter 2026 Financial Results on May 12, 2026
SCOTTSDALE, Ariz., April 21, 2026 /PRNewswire/ — Resideo Technologies, Inc. (NYSE: REZI), a leading global manufacturer, developer, and distributor of…
Read More » -
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
SAN DIEGO, April 21, 2026 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company…
Read More » -
ISCT Announces Inaugural CGT Clinical Applications Program for Clinical Fellows
VANCOUVER, BC, April 21, 2026 /PRNewswire/ – The International Society for Cell & Gene Therapy (ISCT) Institute of Training & Development…
Read More »








